Clinical Pipeline

Sort by:

Indication

Molecule

Indication

Study

Line & Regimen

Indication:

Lung Cancer

Study: 
                  
Line & Regimen : 
              1L, PD-L1 ≥ 50%
              
                            dom + zim ± etruma vs. zim
            
Phase 1 
Phase 1b 
Phase 2
Phase 3
Study: 
                  
Line & Regimen> : 

              1L, 2L
                            
                            dom + zim ± quemli ± chemo 
            
Phase 1 
Phase 1b 
Phase 2
Phase 3
Study: 
                  
Line & Regimen> : 

              1L, 2L
                            
                            dom ± zim ± etruma ± 
sacituzumab govitecan
            
Phase 1 
Phase 1b 
Phase 2
Phase 3
Study: 
                  
Line & Regimen> : 

              1L, PD-L1 ≥ 50%
                            
                            dom + zim vs. pembro
            
Phase 1 
Phase 1b 
Phase 2
Phase 3
Study: 
                  
Line & Regimen> : 

              Stage III, unresectable, PD-L1≥1%
                            
                            dom + durvalumab vs. durvalumab
            
Phase 1 
Phase 1b 
Phase 2
Phase 3
Study: 
                  
Line & Regimen> : 

              1L
                            
                            dom + zim + chemo vs.
pembro + chemo
            
Phase 1 
Phase 1b 
Phase 2
Phase 3

Indication:

Prostate Cancer

Study:

Line & Regimen :

2L+
etruma + zim + doce vs. doce etruma + sacituzumab govitecan ± zim

Phase 1

Phase 1b

Phase 2

Phase 3

Indication:

Colorectal Cancer

Study:

Line & Regimen :

2L
etruma + zim + FOLFOX* vs. FOLFOX*

Phase 1

Phase 1b

Phase 2

Phase 3

Study:

Line & Regimen> :

3L
etruma + zim + FOLFOX* vs. rego

Phase 1

Phase 1b

Phase 2

Phase 3

Indication:

Pancreatic Cancer

Study:

Line & Regimen :

1L
quemli + zim + gem/nab-pac vs. quemli + gem/nab-pac

Phase 1

Phase 1b

Phase 2

Phase 3

Study:

Line & Regimen> :

2L
quemli + zim + gem/nab-pac

Phase 1

Phase 1b

Phase 2

Phase 3

Indication:

Gastrointestinal Cancer

Study: 
                  
Line & Regimen : 
              1L
              
                            dom ± zim ± FOLFOX
            
Phase 1 
Phase 1b 
Phase 2
Phase 3
Study: 
                  
Line & Regimen> : 

              2L
                            
                            dom ± zim ± quemli
            
Phase 1 
Phase 1b 
Phase 2
Phase 3
Study: 
                  
Line & Regimen> : 

              1L
                            
                            dom + zim + chemo vs.
nivo + chemo
            
Phase 1 
Phase 1b 
Phase 2
Phase 3

Indication:

Advanced Malignancies, Including RCC

Study:

Line & Regimen :

2L+
AB521

Phase 1

Phase 1b

Phase 2

Phase 3

Indication:

Healthy Participants

Study:

Line & Regimen :

AB521

Phase 1

Phase 1b

Phase 2

Phase 3

Molecule:

Domvanalimab
(DOM)

FC-SILENT ANTI-TIGIT ANTIBODY

Indication:Lung Cancer
Study:
                  
Line & Regimen:
              1L, PD-L1 ≥ 50%

              dom + zim ± etruma vs. zim
            
Phase 1
Phase 1b
Phase 2
Phase 3
Indication:Lung Cancer
Study:
                  
Line & Regimen:

              1L, 2L

              dom + zim ± quemli ± chemo
            
Phase 1
Phase 1b
Phase 2
Phase 3
Indication:Lung Cancer
Study:
                  
Line & Regimen:

              1L, 2L

              dom ± zim ± etruma ± sacituzumab govitecan
            
Phase 1
Phase 1b
Phase 2
Phase 3
Indication:Lung Cancer
Study:
                  
Line & Regimen:

              1L, PD-L1 ≥ 50%

              dom + zim vs. pembro
            
Phase 1
Phase 1b
Phase 2
Phase 3
Indication:Lung Cancer
Study:
                  
Line & Regimen:

              Stage III, unresectable, PD-L1≥1%

              dom + durvalumab vs. durvalumab
            
Phase 1
Phase 1b
Phase 2
Phase 3
Indication:Lung Cancer
Study:
                  
Line & Regimen:

              1L

              dom + zim + chemo vs. pembro + chemo
            
Phase 1
Phase 1b
Phase 2
Phase 3
Indication:Gastrointestinal Cancer
Study:
                  
Line & Regimen:

              1L

              dom ± zim ± FOLFOX
            
Phase 1
Phase 1b
Phase 2
Phase 3
Indication:Gastrointestinal Cancer
Study:
                  
Line & Regimen:

              2L

              dom ± zim ± quemli
            
Phase 1
Phase 1b
Phase 2
Phase 3
Indication:Gastrointestinal Cancer
Study:
                  
Line & Regimen:

              1L

              dom + zim + chemo vs.
nivo + chemo
            
Phase 1
Phase 1b
Phase 2
Phase 3

Molecule:

Quemliclustat

CD73 Inhibitor Small Molecule

Indication:Lung Cancer
Study:
                  
Line & Regimen:
              1L, 2L

              dom + zim ± quemli ± chemo
            
Phase 1
Phase 1b
Phase 2
Phase 3
Indication:GASTROINTESTINAL CANCER
Study:
                  
Line & Regimen:

              2L

              dom ± zim ± quemli
            
Phase 1
Phase 1b
Phase 2
Phase 3
Indication:Pancreatic Cancer
Study:
                  
Line & Regimen:

              1L

              quemli + zim + gem/nab-pac vs. quemli + gem/nab-pac
            
Phase 1
Phase 1b
Phase 2
Phase 3
Indication:Pancreatic Cancer
Study:
                  
Line & Regimen:

              2L

              quemli + zim + gem/nab-pac
            
Phase 1
Phase 1b
Phase 2
Phase 3

Molecule:

Etrumadenant
(ETRUMA)

Dual A_2a/A_2b Adenosine Receptor Antagonist Small Molecule

Indication:Lung Cancer
Study:
                  
Line & Regimen:
              1L, PD-L1 ≥ 50%

              dom + zim ± etruma vs. zim
            
Phase 1
Phase 1b
Phase 2
Phase 3
Indication:Lung Cancer
Study:
                  
Line & Regimen:

              1L, 2L

              dom ± zim ± etruma ± sacituzumab govitecan
            
Phase 1
Phase 1b
Phase 2
Phase 3
Indication:Prostate Cancer
Study:
                  
Line & Regimen:

              2L

              etruma + zim + doce vs. doce
etruma + sacituzumab govitecan ± zim
            
Phase 1
Phase 1b
Phase 2
Phase 3
Indication:Colorectal Cancer
Study:
                  
Line & Regimen:

              2L

              etruma + zim + FOLFOX* vs. FOLFOX*
            
Phase 1
Phase 1b
Phase 2
Phase 3
Indication:Colorectal Cancer
Study:
                  
Line & Regimen:

              3L

              etruma + zim + FOLFOX* vs. rego
            
Phase 1
Phase 1b
Phase 2
Phase 3

Molecule:

AB521

HIF-2𝛂 Inhibitor

Indication:

Healthy Participants

Study:

Line & Regimen:

AB521

Phase 1

Phase 1b

Phase 2

Phase 3

Indication:

Advanced Malignancies, including RCC

Study:

Line & Regimen:

2L+
AB521

Phase 1

Phase 1b

Phase 2

Phase 3

Key Compounds Being Studied:

Etruma

Etrumadenant

Dual A2aR/A2bR Antagonist Small Molecule

Quemli

Quemliclustat

CD73 Inhibitor Small Molecule

Dom

Domvanalimab

anti-TIGIT mAb

Zim

Zimberelimab

anti-PD-1 mAb

Abbreviations:

atezo: atezolizumab; bev: bevacizumab; carbo/pem: carboplatin/pemetrexed; doce: docetaxel; dom: domvanalimab; enza: enzalutamide; etruma: etrumadenant; gem/nab-pac: gemcitabine/nab-paclitaxel; nivo: nivolumab; pembro: pembrolizumab; PLD: pegylated liposomal doxorubicin; quemli: quemliclustat; rego: regorafenib; SOC: standard of care; zim: zimberelimab

*+/- biologic, e.g. bevacizumab or biosimilar, will be included for all patients in whom it is not contraindicated.

Partnerships & Collaborations

View Details

View Details

View Details

DISCOVERY PIPELINE

IMMUNO-ONCOLOGY TARGET

Anti-CD39

Exo-nucleotidase

CD39 is a key enzyme in removing ATP from the tumor microenvironment; increased ATP may enhance the adaptive immune response against tumors.¹

Additional undisclosed targets.

CANCER CELL INTRINSIC TARGET

AXL Inhibitor

Tyrosine kinase

AXL overexpression is associated with tumor resistance to chemotherapy
and immunotherapy drugs.²

Additional undisclosed targets.

References: 1. Moesta et al. Targeting CD39 in Cancer. Nat Rev Immunol. Volume 20, pages 739–755 (2020). 2. Axelrod HD, Valkenburg KC, Amend SR, et al. AXL is a putative tumor suppressor and dormancy regulator in prostate cancer. Mol Cancer Res. 2019;17(2):356-369.

Clinical Pipeline

DISCOVERY PIPELINE

Explore More